FDA Grants Breakthrough Status to Biogen’s Lupus Skin Therapy

On Jan 30, 2026

The Lupus Research Alliance has welcomed the U.S. Food and Drug Administration’s decision to grant Breakthrough Therapy designation to litifilimab (BIIB059), an investigational treatment being developed by Biogen Inc. for cutaneous lupus erythematosus (CLE). The designation highlights the therapy’s potential to address a significant unmet medical need in a chronic autoimmune skin condition that currently has no specifically approved treatments.

Breakthrough Therapy designation is reserved for drugs that may demonstrate substantial improvement over existing therapies for serious or life-threatening diseases. The status is intended to speed the development and regulatory review process through closer collaboration with the FDA, with the goal of making promising treatments available to patients more quickly.

CLE is a common manifestation of lupus, a complex autoimmune disease that can affect multiple organs and systems. In CLE, inflammation primarily targets the skin, leading to symptoms such as butterfly-shaped facial rashes, ring-like lesions, and red, scaly patches. In many cases, the disease can cause permanent scarring, changes in skin pigmentation, and hair loss, all of which can have a profound impact on patients’ quality of life and emotional wellbeing.

According to the Lupus Research Alliance, between 70% and 85% of people living with lupus experience cutaneous symptoms at some point during their disease course. Albert T. Roy, President and Chief Executive Officer of the Lupus Research Alliance, said the FDA’s decision represents a critical step forward for patients with CLE. He emphasized that there are currently no therapies specifically approved for this condition, making the advancement of litifilimab particularly important.

Roy also pointed to decades of research supported by the Lupus Research Alliance that helped lay the scientific foundation for treatments like litifilimab. Research funded more than 20 years ago identified type I interferons as key drivers of inflammation in lupus, a discovery that has since informed multiple therapeutic approaches. Litifilimab targets this pathway by binding to BDCA2, a receptor involved in interferon production.

Litifilimab is a humanized IgG1 monoclonal antibody, and the Breakthrough Therapy designation was granted based on results from Biogen’s Phase 2 LILAC study. The drug is now being evaluated in a Phase 3 clinical trial known as AMETHYST, which is assessing its safety and efficacy in patients with CLE.

The Lupus Research Alliance and its clinical affiliate, Lupus Therapeutics, have played an ongoing role in the development of litifilimab. Lupus Therapeutics has collaborated with Biogen on both Phase 2 and Phase 3 trials, helping to ensure that patient perspectives are incorporated throughout the development process. Several studies are also led by investigators from the Lupus Clinical Investigators Network (LuCIN).

Biogen is additionally a member of the Lupus Accelerating Breakthroughs Consortium, a public-private partnership convened by the Lupus Research Alliance in collaboration with the FDA. The consortium includes a dedicated working group focused on CLE, aimed at accelerating the development of safer and more effective treatments for people living with this challenging condition.